Subscribe for real-time financial insights on Trade Target’s WhatsApp Channels
Emcure Pharmaceuticals Limited, founded in 1981 is an Indian company that develops, manufactures and markets wide range of pharmaceutical products globally.
By September 2023 Emcure was ranked 13th in domestic sales among Indian pharmaceutical companies and held 4th largest market share in its areas of operation. It was also top company in gynecology and HIV antiviral treatments.
In first half of 2023 and entire financial year domestic sales made up over half of Emcure’s revenue. From 2019 to 2023, these sales grew at an annual rate of 10.80%, outpacing overall Indian pharmaceutical market.
Emcure employs 552 scientists across five research facilities in India. By September 2023 they had filed over 1,800 documents worldwide including 204 in the EU and 133 in Canada with 201 granted patents 33 pending patent applications and 102 drug master files submitted.
The company operates 13 manufacturing facilities in India producing variety of pharmaceutical and biopharmaceutical products. Their capabilities include manufacturing pills, liquids, injectables and complex ingredients like chiral molecules, iron molecules, and cytotoxic substances.
Emcure’s marketing and distribution network in India includes over 5,000 field personnel and more than 5,000 stockists supported by 37 carry-and-forward agents, ensuring regular interaction with healthcare providers.
Emcure Pharmaceuticals IPO Overview
Emcure Pharma is launching an IPO worth Rs 1,952.03 crores. This includes a fresh issue of shares valued at Rs 800 crores and an offer for sale of shares worth Rs 1,152.03 crores.
The IPO will be open for subscription from July 3 to July 5, 2024. The share allotment is expected to be finalized on July 8, 2024, and the shares are likely to be listed on the BSE and NSE on July 10, 2024.
The price range for the IPO is set between ₹960 and ₹1008 per share. Satish Mehta and Sunil Mehta promoted the company. Before the IPO, the promoters hold 98.90% of the shares.
Link Intime India Private Ltd. is the registrar for this IPO.
Emcure Pharmaceuticals IPO GMP
Emcure Pharma’s IPO has a last grey market premium (GMP) of ₹270 as of June 28th, 2024, at 1:56 PM. With a price band set at ₹1008, the estimated listing price is ₹1278 (the upper price band plus today’s GMP). This suggests an expected gain of 26.79% per share.
Stay tuned with Trade Target for daily updates on Emcure Pharmaceuticals IPO GMP and the expected listing price.
- Date: 7– July – 2024
- Emcure Pharmaceuticals GMP: ₹390 (38.69%)
- Date: 6– July – 2024
- Emcure Pharmaceuticals GMP: ₹390 (38.69%)
- Date: 5– July – 2024
- Emcure Pharmaceuticals GMP: ₹371 (36.81%)
- Date: 4– July – 2024
- Emcure Pharmaceuticals GMP: ₹335 (33.23%)
- Date: 3– July – 2024
- Emcure Pharmaceuticals GMP: ₹330 (32.74%)
- Date: 2– July – 2024
- Emcure Pharmaceuticals GMP: ₹299 (29.66%)
- Date: 1– July – 2024
- Emcure Pharmaceuticals GMP: ₹285 (28.27%)
- Date: 30– June – 2024
- Emcure Pharmaceuticals GMP: ₹264 (26.19%)
- Date: 29– June – 2024
- Emcure Pharmaceuticals GMP: ₹264 (26.19%)
- Date: 28– June – 2024
- Emcure Pharmaceuticals GMP: ₹271 (26.88%)
How can one apply for Emcure Pharmaceuticals IPO?
Investors interested in the Emcure Pharma IPO can start by bidding for at least 14 shares, with bids in multiples of 14 shares thereafter. Here’s a breakdown of the minimum and maximum investments for retail and high net worth investors (HNI):
| Application | Lots | Shares | Amount |
|---|---|---|---|
|
Retail (Min) |
1 |
14 |
₹14,112
|
|
Retail (Max) |
14 |
196 |
₹197,568
|
|
S-HNI (Min) |
15 |
210 |
₹211,680
|
|
S-HNI (Max) |
70 |
980 |
₹987,840
|
|
B-HNI (Min)
|
71 |
994 |
₹1,001,952
|
Emcure Pharmaceuticals IPO Financial
For the financial years ending March 31, 2024, 2023, and 2022, the company’s key financial figures are as follows:
| Period Ended | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
|---|---|---|---|
|
Assets in (₹ Crores) |
7,806.16
|
6,672.53
|
6,063.47
|
|
Revenue (₹ Crores) |
6,715.24
|
6,031.72
|
5,918.86
|
|
PAT (₹ crores)
|
527.58
|
561.85
|
702.56
|
|
Total Borrowing (₹ crores)
|
2,091.94 |
2,202.42
|
2,102.19
|
Emcure Pharmaceuticals Vs Peers
This table highlights the earnings per share and the price-to-earnings ratios of various pharmaceutical companies.
| Company | EPS Diluted | P/E(x) |
|---|---|---|
|
Emcure Pharmaceuticals Limited
|
27.54 |
- |
|
Dr. Reddy's Laboratories Limited
|
335.59
|
17.93
|
|
Cipla Ltd.
|
51.01
|
30.1
|
|
Alkem Laboratories Ltd
|
150.19
|
33.86
|
|
Torrent Pharmaceuticals Ltd.
|
48.94
|
57.74
|
|
Mankind Pharma Limited
|
47.68
|
45.3 |
|
Abbott India Ltd.
|
565.28
|
47.43
|
|
J. B. Chemicals & Pharmaceuticals Limited
|
34.85
|
50.49
|
Emcure Pharmaceuticals IPO Quota allocation
- QIB Investors: 50% of the net issue
- Retail Investors: 35% of the net issue
- NII (HNI) Investors: 15% of the net issue
Expected Listing Date for Emcure Pharmaceuticals IPO
- Subscription Period: 3 July to 5 July
- Basis of Allotment Finalization: 8 July 2024
- Initiation of Refunds: 9 July 2024
- Demat Credits: 9 July 2024
- Listing Date: 10 July 2024
- Listing on: NSE, BSE
